NCT02916095View on ClinicalTrials.gov

Kanitinib in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

July 31, 2020

Conditions
Solid Tumors
Interventions
DRUG

Kanitinib

Oral administration of Kanitinib tablets.

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY

NCT02916095 - Kanitinib in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter